Unilever Acquires Greens Supplement Brand Grüns to Boost Wellness Portfolio

Unilever agreed to acquire Grüns, the three-year-old greens supplement startup, in a deal valued at $1.2 billion, the company's most aggressive bet yet on a wellness category that sits squarely in the regulatory gray zone between food and medicine.

Unilever announced it will buy U.S.-based nutritional supplements brand Grüns for an undisclosed amount, though the deal is worth $1.2 billion, according to Axios Pro reporting. Founded in 2023 by former private equity investor Chad Janis, Grüns makes nutrient-dense gummies from vegetables and fruits, claiming to deliver 21 vitamins and minerals per serving. Grüns was valued at $500 million in a Series B investment round in 2025, meaning Unilever's agreed price represents more than double that figure in under a year.

The transaction is the fourth supplement acquisition Unilever has completed since 2019. The British group bought hair growth supplements brand Nutrafol in 2022, SmartyPants Vitamins in 2020, and gummy vitamins brand Olly Nutrition in 2019. This is also Unilever's first acquisition since it agreed last month to merge its food business with spice-maker McCormick, creating a $65 billion food giant, signaling that the stripped-down Unilever intends to build its identity around premium wellness products rather than legacy grocery staples.

That identity, however, comes with a regulatory asterisk. Unlike prescription drugs or even over-the-counter medications, dietary supplements are not subject to FDA pre-market approval. The Dietary Supplement Health and Education Act of 1994 (DSHEA) established a regulatory framework that authorized structure/function claims on supplement labels, such as "supports immune health" or "promotes energy," provided manufacturers can substantiate that the claim is truthful and not misleading. The standard of proof is set by the company itself, not by an independent agency. Since the FDA doesn't approve or regulate supplements in the same way as prescription drugs, it's up to manufacturers to ensure customer safety.

Grüns has sought to differentiate itself on that front. The company says its products are manufactured in NSF, GMP, and FDA-registered facilities in the U.S. and Canada, and it conducts testing through Eurofins Scientific to validate label claims across 21 vitamins and minerals and to screen for 99 pesticides, heavy metals, and microbial contaminants. Those are meaningful quality signals, but they remain voluntary commitments, not regulatory mandates.

Whether Unilever's ownership reinforces or dilutes that posture is the central question for the brand's million-plus customers. On the optimistic side, Unilever's manufacturing infrastructure and compliance machinery could raise the floor on quality control across the product line. The concern runs in the other direction: a $1.2 billion acquisition premium demands accelerated revenue, which historically pushes consumer brands toward broader health claims, wider retail placement, and intensified digital advertising. Grüns is already sold at Target, Walmart, Costco, Sam's Club, and Sprouts. Unilever's global distribution footprint could extend that shelf presence internationally, and its marketing engine could bring far more spending power behind claims that the FDA has not independently verified.

Jostein Solheim, Unilever Wellbeing CEO, pointed to the brand's consumer loyalty as the acquisition's core rationale. "What sets Grüns apart is its focused portfolio of science-backed products that people genuinely enjoy, trust, and consistently use," he said. Janis framed the deal in similar terms: "With Unilever behind us, we can reach more people, move faster, and continue raising the bar on what an enjoyable daily wellness habit can be."

Unilever's Health and Wellbeing business had crossed $1 billion in revenue by 2023, and the Grüns deal signals the company's intent to push that figure substantially higher. For supplement buyers, the practical implications will likely arrive as higher shelf prices as the brand moves upmarket, heavier social media advertising, and the inevitable question of whether the science behind a gummy made by a startup in 2023 holds up at the scale of a global consumer goods empire.